The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis

References

• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933. doi:10.1016/j.jacc.2010.04.047
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F. The paradox of smoking and clopidogrel effect. Circulation J 2016;80:1529–1531. doi:10.1253/circj.CJ-16-0508
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015;12:30–47. doi:10.1038/nrcardio.2014.156
   PubMed Web of Science ®Google Scholar
• Machii R, Saika K. Mortality attributable to tobacco by region based on the WHO global report. Jpn J Clin Oncol 2012;42:464–465. doi:10.1093/jjco/hys063
   PubMed Web of Science ®Google Scholar
• Lin MP, Ovbiagele B, Markovic D, Towfighi A. Association of secondhand smoke with stroke outcomes. Stroke 2016;47:2828–2835. doi:10.1161/STROKEAHA.116.014099
   PubMedGoogle Scholar
• He Y, Jiang B, Li LS, Li LS, Sun DL, Wu L, Liu M, He SF, Liang BQ, Hu FB, et al. Changes in smoking behavior and subsequent mortality risk during a 35-year follow-up of a cohort in Xi’an, China. Am J Epidemiol 2014;179:1060–1070. doi:10.1093/aje/kwu011
   PubMed Web of Science ®Google Scholar
• Shah AM, Pfeffer MA, Hartley LH, Moyé LA, Gersh BJ, Rutherford JD, Lamas GA, Rouleau JL, Braunwald E, Solomon SD. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am J Cardiol 2010;106:911–916. doi:10.1016/j.amjcard.2010.05.021
   PubMed Web of Science ®Google Scholar
• Mobarrez F, Antoniewicz L, Bosson JA, Kuhl J, Pisetsky DS, Lundbäck M. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One 2014;9:e90314. doi:10.1371/journal.pone.0090314
   PubMed Web of Science ®Google Scholar
• Sibbing D, Gross L. Smoking and clopidogrel response revisited: hemoglobin levels explaining the smoker’s paradox. Jacc 2016;9:1691–1693. doi:10.1016/j.jcin.2016.06.042
   PubMed Web of Science ®Google Scholar
• Ghahremanfard F, Semnani V, Ghorbani R, Malek F, Behzadfar A, Zahmatkesh M. Effects of cigarette smoking on morphological features of platelets in healthy men. Saudi Med J 2015;36:847–850. doi:10.15537/smj.2015.7.11026
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O’Donoghue ML, Bernlochner I, Contant CF, Guo J, et al. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 2011;162:518–526.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, Capranzano P, Kodali M, Dharmashankar K, Charlton RK, et al. Cigarette smoking is associated with a dose–response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv 2012;5:293–300. doi:10.1016/j.jcin.2011.09.027
   PubMed Web of Science ®Google Scholar
• Park KW, Kang SH, Kang J, Jeon KH, Park JJ, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of ‘smokers’ paradox’. Heart 2012;98:1000–1006. doi:10.1136/heartjnl-2011-301565
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–1105. doi:10.1001/jama.2011.290
   PubMed Web of Science ®Google Scholar
• Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162:160–165. doi:10.1016/j.ahj.2010.11.025
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Bhatt DL, Ueno M, Bauer D, Angiolillo DJ. Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel versus aspirin in patients at risk of ischemic events). J Am Coll Cardiol 2014;63:769–777. doi:10.1016/j.jacc.2013.10.043
   PubMedGoogle Scholar
• Chen KY, Rha SW, Li YJ, Jin Z, Minami Y, Park JY, Poddar KL, Ramasamy S, Wang L, Li GP, et al. Smoker’s paradox in young patients with acute myocardial infarction. Clin Exp Pharmacol Physiol 2012;39:630–635. doi:10.1111/j.1440-1681.2012.05721.x
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171–3175. doi:10.1161/01.CIR.0000130846.46168.03
   PubMed Web of Science ®Google Scholar
• Bellemain-Appaix A, Montalescot G, Silvain J, Barthélémy O, Beygui F, Collet JP, Sideris G, Meuleman C, Bal-Dit-Sollier C, Lellouche N, et al. Slow response to clopidogrel predicts low response. J Am Coll Cardiol 2010;55:815–822. doi:10.1016/j.jacc.2009.08.082
   PubMed Web of Science ®Google Scholar
• Zhao Z-G, Chen M, Peng Y, Chai H, Liu W, Li Q, Ren X, Wang XQ, Luo XL, Zhang C, et al. The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis. Heart 2014;100:192–199. doi:10.1136/heartjnl-2013-304138
   PubMed Web of Science ®Google Scholar
• Oremus M, Oremus C, Hall GB, McKinnon MC. ECT & Cognition Systematic Review Team. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open 2012;2:e001368. doi:10.1136/bmjopen-2012-001368
   PubMed Web of Science ®Google Scholar
• Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007;36:666–676. doi:10.1093/ije/dym018
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Deeks JJ. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011 March-[cited 2018 Apr 12]; Available from: http://www.cochrane-handbook.org
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45:139–145. doi:10.1016/j.cct.2015.09.002
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011;39:91–92. doi:10.1016/j.jcms.2010.11.001
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.
   PubMed Web of Science ®Google Scholar
• Kim YG, Suh JW, Kang SH, Park JJ, Yoon CH, Cho YS, Youn TJ, Chae IH, Choi DJ, Kim HS. Cigarette smoking does not enhance clopidogrel responsiveness after adjusting VerifyNow P2Y12 reaction unit for the influence of hemoglobin level. JACC Cardiovasc Interv 2016;9:1680–1690. doi:10.1016/j.jcin.2016.05.036
   PubMed Web of Science ®Google Scholar
• Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012;30:5–11. doi:10.1111/j.1755-5922.2010.00249.x
   PubMed Web of Science ®Google Scholar
• Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJ. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: insights from the GRAVITAS trial. Catheter Cardiovasc Interv 2017;89:190–198. doi:10.1002/ccd.26428
   PubMed Web of Science ®Google Scholar
• Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339–1343. doi:10.1016/j.amjcard.2009.01.341
   PubMed Web of Science ®Google Scholar
• Maruyama H, Fukuoka T, Deguchi I, Ohe Y, Horiuchi Y, Kato Y, Sehara Y, Nagamine Y, Sano H, Hayashi T, et al. Relationship between smoking and responsiveness to clopidogrel in non-cardiogenic ischemic stroke patients. Intern Med. 2014;53:2575–2579.
   PubMed Web of Science ®Google Scholar
• Jeong YH, Cho JH, Kang MK, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY. Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thromb Res 2010;126:e334–338. doi:10.1016/j.thromres.2010.03.020
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb Res 2009;124:588–591. doi:10.1016/j.thromres.2009.06.012
   PubMed Web of Science ®Google Scholar
• Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, Bailey WL, Tantry US, Gurbel PA. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531–533. doi:10.1016/j.jacc.2008.04.045
   PubMed Web of Science ®Google Scholar
• Weisz G, Kirtane AJ, Xu K, Stuckey T, Witzenbichler B, Rinaldi M, Neumann FJ, Metzger DC, Henry TD, Cox D, et al. The effect of smoking status on platelet reactivity and long-term events after PCI. Does a clopidogrel-related “smoker’s paradox” exist? 25th Annual Symposium on Transcatheter Cardiovascular Therapeutics (TCT); 2013 Oct 27-Nov 01; San Francisco, CA: J Am Coll Cardiol; 2013.62(18): B50.
   Google Scholar
• Cho JH, Jeong YH, Ahn YJ, Kang MK, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY. The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction. Korean Circ J 2010;40:119–124. doi:10.4070/kcj.2010.40.3.119
   PubMedGoogle Scholar
• Studts J, Ghate SR, Jill JL, Studts CR, Barnes CN, LaJoie AS, Andrykowski MA, LaRocca RV. Validity of self-reported smoking status among participants in a lung cancer screening trial. Cancer Epidemiol Biomarkers Prev 2006;15:1825–1828. doi:10.1158/1055-9965.EPI-06-0393
   PubMed Web of Science ®Google Scholar
• Aune E, Røislien J, Mathisen M, Thelle DS, Otterstad JE. The “smoker’s paradox” in patients with acute coronary syndrome: a systematic review. BMC Med 2011;23:97. doi:10.1016/j.jcin.2015.07.010
   Google Scholar
• Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM, Topol EJ, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009;120:2337–2344. doi:10.1161/CIRCULATIONAHA.109.866533
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Wang J, Johnston SC, Wang A, Wang D, Wang Y, Zhao X, Wang Y. Effect of clopidogrel by smoking status on secondary stroke prevention. Circulation 2017;135:315–316. doi:10.1161/CIRCULATIONAHA.116.024957
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502. doi:10.1056/NEJMoa010746
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, Topol EJ, Investigators CREDO. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–2420.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (CLOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. The Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607–1621. doi:10.1016/S0140-6736(05)67660-X
   PubMed Web of Science ®Google Scholar
• Patti G, Polacco M, Taurino E, Gaudio C, Greco C. Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drugeluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study. J Thromb Thrombolysis 2016;41:648–653. doi:10.1007/s11239-016-1341-8
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013;73:1681–1709. doi:10.1007/s40265-013-0126-z
   PubMed Web of Science ®Google Scholar
• GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015;385:117–171. doi:10.1016/S0140-6736(14)61682-2
   PubMed Web of Science ®Google Scholar
• Washio I, Maeda M, Sugiura C, Shiga R, Yoshida M, Nonen S, Fujio Y, Azuma J. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011;39:1–3. doi:10.1124/dmd.110.034504
   PubMed Web of Science ®Google Scholar
• Bliden KP, Baker BA, Nolin TD, Jeong YH, Bailey WL, Tantry US, Gurbel PA. Thienopyridine efficacy and cigarette smoking status. Am Heart J 2013;165:693–703. doi:10.1016/j.ahj.2012.12.024
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126–142. doi:10.1177/0091270009343005
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268–354. doi:10.3109/03602530903286476
   PubMed Web of Science ®Google Scholar
• Gengo F, Robson M, Rainka M. CYP1A2-inducing medications improve platelet responsiveness to clopidogrel. J Clin Pharmacol. 2010;50:1069.
   Web of Science ®Google Scholar
• Cornel JH, Ohman EM, Neely B, Clemmensen P, Sritara P, Zamoryakhin D, Armstrong PW, Prabhakaran D, White HD, Fox KA, et al. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: insights from the TRILOGY ACS trial. Am Heart J 2014;168:76–87. doi:10.1016/j.ahj.2014.04.011
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505–512. doi:10.1016/j.jacc.2013.03.037
   PubMed Web of Science ®Google Scholar
• Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members; Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: A report of the American college of cardiology foundation task force on clinical expert consensus documents and the American heart association. Circulation 2010;122:537–557. doi:10.1161/CIR.0b013e3181ee08ed
   PubMed Web of Science ®Google Scholar
• Valenti R, Marcucci R, Comito V, Marrani M, Cantini G, Migliorini A, Parodi G, Gensini GF, Abbate R, Antoniucci D. Prasugrel in clopidogrel nonresponders undergoing percutaneous coronary intervention: the RECLOSE-3 study (Responsiveness to Clopidogrel and Stent Thrombosis). JACC Cardiovasc Interv 2015;8:1563–1570. doi:10.1016/j.jcin.2015.07.010
   PubMedGoogle Scholar